Roche Holding AG is making good on its promise to try and convince the EMA of the benefits of Elevidys (delandistrogene moxeparvovec), announcing a further global phase III trial of the Duchenne muscular dystrophy gene therapy.
Chugai Pharmaceutical has reported a new humanized antibody (Ab, SOF-10) that targets latent TGF-β1 and selectively blocks protease- and integrin αVβ8-mediated latent TGF-β1 activation.
Intratumoral regulatory T cells (Tregs) suppress antitumor immunity and are linked to poor prognosis across many cancers. These tumor-infiltrating Tregs express high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), making them attractive targets for immunotherapy. However, systemic Treg depletion carries the risk of severe autoimmune toxicity.
Chugai Pharmaceutical Co. Ltd. and Rani Therapeutics LLC have entered into a collaboration and global license agreement to develop and commercialize an oral product that encompasses Rani’s oral delivery technology, the Ranipill, and Chugai’s rare disease antibody in development.
Chugai Pharmaceutical Co. Ltd. and Rani Therapeutics LLC have entered into a collaboration and global license agreement to develop and commercialize an oral product that encompasses Rani’s oral delivery technology, the Ranipill, and Chugai’s rare disease antibody in development.
Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL-6 receptor (IL-6R) humanized antibody approved for preventing relapses in NMOSD (AQP4 IgG positive) in adults and children in Japan.
Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human data-first platform.
Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human data-first platform.
Chugai Pharmaceutical Co. Ltd. and Gero Pte Ltd. have entered into a joint research and license agreement to develop novel therapies for age-related diseases. Chugai will create novel antibody-drug candidates for new drug targets discovered by Gero using its AI target discovery platform.
Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.
